Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 03:36:51 19/02/26 am AEDT			5-day change	1st Jan Change
45.81 ^EUR	-7.11%		-0.68%	+23.78%

19/02	Ad giant Omnicom posts upbeat quarterly revenue on boost from IPG acquisition, new clients	RE
19/02	Europe's STOXX 600 closes at record high on earnings boost; ECB leadership shift in focus	RE

Bayer slows after strong recovery, valuation stretched

After an 87% year-to-date rebound to two-year highs, Bayer trades around 18x 2027e P/E versus c.14x for AV Big Pharmas. Markets may be pricing a near-term Glyphosate litigation resolution, leaving limited upside and a case for waiting on pullbacks.

Published on 12/17/2025 at 07:41 pm AEDT - Modified on 12/17/2025 at 07:14 pm AEDT

Alphavalue

Bayer slows after strong recovery, valuation stretched

This article is reserved for subscribers.

Alphavalue, the European leader in independent research, is exclusively available on MarketScreener.

To unlock the article, subscribe!

Latest news about Bayer AG

19/02	Ad giant Omnicom posts upbeat quarterly revenue on boost from IPG acquisition, new clients	RE
19/02	Europe's STOXX 600 closes at record high on earnings boost; ECB leadership shift in focus	RE
19/02	German Blue-chip DAX Closes Higher; Bayer Plunges on Lawsuit Settlement Proposal	MT
19/02	Bayer: Almost out of the Roundup litigation woods
19/02	Paris and Other European Markets Rally Despite Geopolitical Tensions
18/02	DZ Bank Downgrades Bayer to 'Sell' - Planning Security Comes at a High Price	DP
18/02	Bayer Shares Reverse Gains After Plan to Settle Roundup Litigation	DJ
18/02	BAYER AG : Downgraded from Buy to Sell by DZ Bank	ZD
18/02	Bayer retreats as investors sour on deal to settle Roundup litigation	RE
18/02	Confidence Prevails on European Markets Despite Wall Street Uncertainty
18/02	Bayer shares slide after unveiling plan to settle Roundup-related litigation in the US
18/02	Bayer's Settlement Euphoria Fades as Shares Plunge	DP
18/02	Bayer Euphoria Fades – Significant Share Losses	DP
18/02	Bayer Reaches Multi-Billion Dollar Glyphosate Settlement in the US	RE
18/02	BAYER AG : UBS reaffirms its Neutral rating	ZD

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

88,502

Sector

Pharmaceuticals

Calendar

25/02 - Q4 2025 Earnings Release

More about the company